BridgeBio Pharma (BBIO) News Today $36.74 -0.48 (-1.29%) Closing price 04:00 PM EasternExtended Trading$36.72 -0.02 (-0.05%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BridgeBio Pharma (NASDAQ:BBIO) Trading 8.9% Higher After Analyst UpgradeBridgeBio Pharma (NASDAQ:BBIO) Trading Up 8.9% on Analyst UpgradeMarch 25 at 3:11 PM | marketbeat.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) StockJPMorgan Chase & Co. upped their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the company an "overweight" rating in a research report on Monday.March 25 at 9:19 AM | marketbeat.com13,155 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Cibc World Markets CorpCibc World Markets Corp purchased a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 13,155 shares of the company's stock, valued at approximaMarch 25 at 3:53 AM | marketbeat.comBrokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $52.20March 25 at 1:52 AM | americanbankingnews.comBridgeBio price target raised to $50 from $44 at JPMorganMarch 24 at 5:02 PM | markets.businessinsider.comBridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific SessionsMarch 24 at 7:30 AM | globenewswire.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Emerald Advisers LLCEmerald Advisers LLC raised its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,150,868 shares of the company's stock after purchaMarch 24 at 7:08 AM | marketbeat.comSwiss National Bank Grows Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Swiss National Bank increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 240,300 shares of the company's stock after buying an additMarch 23 at 3:35 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Intech Investment Management LLCIntech Investment Management LLC increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 47.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 65,647 shares of the company's stock aftMarch 22 at 4:45 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eleven analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and ten have assigneMarch 22 at 2:35 AM | marketbeat.comPiper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)March 21, 2025 | markets.businessinsider.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)March 21, 2025 | globenewswire.comBiggest stock movers Friday: NIO, ALNY, FDX, and moreMarch 21, 2025 | msn.comPrimecap Management Co. CA Buys 8,776 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Primecap Management Co. CA lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 915,500 shares of the company's stock after acquiring an additional 8,776 sharMarch 21, 2025 | marketbeat.comKazazian Asset Management LLC Makes New Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Kazazian Asset Management LLC acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 13,520 shares of the company's stock, valued at approximately $371,000. Other instituMarch 20, 2025 | marketbeat.comRoyce & Associates LP Purchases 22,833 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Royce & Associates LP increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 18.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 144,788 shares of the company's stock after acquiringMarch 20, 2025 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - What's Next?BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Here's What HappenedMarch 19, 2025 | marketbeat.comBridgeBio Pharma, Inc.: BridgeBio Announces CFO SuccessionMarch 18, 2025 | finanznachrichten.deBridgeBio CFO Brian Stephenson to depart, Thomas Trimarchi succeedsMarch 18, 2025 | markets.businessinsider.comSkandinaviska Enskilda Banken AB publ Has $1.13 Million Stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Skandinaviska Enskilda Banken AB publ boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 37.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 41,514 shares of the company's stock after buyiMarch 18, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. decreased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 82.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 65,026 shares of the company'March 18, 2025 | marketbeat.comBridgeBio Announces CFO SuccessionMarch 17, 2025 | globenewswire.comWealthfront Advisers LLC Takes Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Wealthfront Advisers LLC bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 21,578 shares of the company's stock, valued at approximMarch 17, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Buys 21,963 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Charles Schwab Investment Management Inc. increased its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 1.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,306,765 shares of the company's stock after purchMarch 17, 2025 | marketbeat.comMonimus Capital Management LP Makes New $1.13 Million Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Monimus Capital Management LP bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 41,077 shares of thMarch 16, 2025 | marketbeat.comBridgeBio Pharma (BBIO) Gets a Buy from J.P. MorganMarch 13, 2025 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: BridgeBio Pharma (BBIO), Johnson & Johnson (JNJ) and Lexicon Pharmaceuticals (LXRX)March 11, 2025 | markets.businessinsider.comEdgestream Partners L.P. Invests $1.54 Million in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Edgestream Partners L.P. acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 56,235 shares of the company's stock, valued at approximately $1,543,000. Other large investoMarch 11, 2025 | marketbeat.comJ.P. Morgan Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)March 8, 2025 | markets.businessinsider.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Genetic Disorder L.P. Kkr Sells 6,000,000 SharesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $32.96, for a total transaction of $197,760,000.00. Following the transaction, the insider now directly owns 19,260,971 shares in the company, valued at approximately $634,841,604.16. This trade represents a 23.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.March 8, 2025 | marketbeat.comGenetic Disorder L.P. Kkr Sells 6,000,000 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockMarch 8, 2025 | insidertrades.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Here's What HappenedBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down - Time to Sell?March 7, 2025 | marketbeat.comKKR Genetic Dosorder L.P. announces sale of 6M shares of BridgeBioMarch 6, 2025 | markets.businessinsider.comBridgeBio prices $575M convertible notes offeringMarch 6, 2025 | markets.businessinsider.comPrediction: BridgeBio Pharma Will Beat the Market. Here's WhyMarch 3, 2025 | fool.comLeerink Partnrs Has Optimistic Outlook of BBIO Q1 EarningsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs lifted their Q1 2025 earnings per share estimates for BridgeBio Pharma in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will post earMarch 1, 2025 | marketbeat.comY Intercept Hong Kong Ltd Increases Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Y Intercept Hong Kong Ltd boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 95.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,980 shares of the company's stock after buMarch 1, 2025 | marketbeat.comBrian C. Stephenson Sells 8,500 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Brian C. Stephenson sold 8,500 shares of BridgeBio Pharma stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total value of $282,115.00. Following the transaction, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,400,780.16. The trade was a 7.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 28, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 75,000 SharesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 75,000 shares of the business's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.57, for a total transaction of $2,517,750.00. Following the transaction, the chief executive officer now directly owns 5,023,447 shares of the company's stock, valued at approximately $168,637,115.79. This represents a 1.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.February 28, 2025 | marketbeat.comBridgeBio price target raised to $46 from $45 at BofAFebruary 28, 2025 | markets.businessinsider.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $282,115.00 in StockFebruary 28, 2025 | insidertrades.comBridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading Volume - Time to Buy?BridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume Increase - Time to Buy?February 27, 2025 | marketbeat.comBridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to AnalystsFebruary 26, 2025 | msn.comWhat is Leerink Partnrs' Estimate for BBIO Q1 Earnings?BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for BridgeBio Pharma in a report released on Monday, February 24th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings per shareFebruary 26, 2025 | marketbeat.comBridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured DebtFebruary 26, 2025 | globenewswire.comQ3 Earnings Estimate for BBIO Issued By Leerink PartnrsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of BridgeBio Pharma in a research report issued to clients and investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar anticipates that the comFebruary 25, 2025 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Recommendation of "Moderate Buy" by BrokeragesBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) has received a consensus rating of "Moderate Buy" from the thirteen brokerages that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and twelve have issued a buyFebruary 25, 2025 | marketbeat.comBridgeBio stock falls on convertible notes offeringFebruary 24, 2025 | investing.comBridgeBio announces offering of convertible senior notes to refinance debtFebruary 24, 2025 | msn.comPeninsula drugmaker nails heart failure drug launch in battle with Big PharmaFebruary 24, 2025 | bizjournals.com Remove Ads Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.930.62▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼187▲BBIO Articles Average Week Remove Ads Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Beigene News BioNTech News Teva Pharmaceutical Industries News Summit Therapeutics News Intra-Cellular Therapies News Moderna News Genmab A/S News Dr. Reddy's Laboratories News Viatris News Ascendis Pharma A/S News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BBIO Stock Free BBIO Stock Alerts